Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MOREReimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewGenerate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWElevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWOrchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWWhen your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTSBy making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MOREBuilding on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MOREYour new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.
LEARN MOREThe IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MOREThe IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MOREIQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MOREEmpowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MORE"At IQVIA your potential has no limits. We thrive on bold ideas and fearless innovation. Join us in reimagining what’s possible.
VIEW ROLESThe lawsuit claims that PBMs effectively collude with manufacturers to subvert competition and maintain artificially high prices. It argues that the PBMs’ administrative fees, which are based on pharmaceutical product revenue, act as a kickback, encouraging the PBMs to not subject pharmaceutical manufacturers to specific cost-saving strategies such as aggressive rebate negotiations, brand drug “therapeutic substitution” and formulary restriction programs.
Manufacturers pay PBMs “administrative fees” ostensibly for their role in providing utilization data, and administering rebates, among other activities in support of the commercial or medical initiatives such as health economic outcomes research or key account planning. In theory, a portion of these administrative fees should be Bona Fide Service Fees based on the application of a Bona Fide Service Fee Test (81 Fed. Reg. 5170 - Feb. 1, 2016), and a detailed Fair Market Value analysis, as outlined in the regulations for Medicare Part D. In reality, the lawsuit contends, all or a significant portion of these administrative fees were treated as Bona Fide Service Fees with a substantial amount representing little more than kickbacks that have little bearing on the actual costs of the services provided.
This high-profile lawsuit and the growing awareness of rising drug prices among elected officials means that the burden of proof is on drug makers to show that the bona fide service fees they pay to PBMs are for specific and quantifiable services rendered. This includes a comprehensive list of the activities performed by the PBMs on behalf of the drug makers, the application of the non-quantitative prongs of the bona fide service fee test and a valuation of the activities.
Companies must consider having a valuation analysis performed contemporaneously with the reporting of the administrative fees. IQVIA Commercial Compliance has the expertise to thoroughly analyze Life Sciences companies’ treatment of PBM administrative fees to ensure it is supported by a thorough analysis that adequately supports the Bona Fide Service Fees paid to the PBMs. IQVIA can help you evaluate the FMV of these PBM service, ensuring they are well supported for compliance and auditing purposes.